{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T23:05:36Z","timestamp":1771369536432,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[1990,1,1]],"date-time":"1990-01-01T00:00:00Z","timestamp":631152000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[1990,1]]},"DOI":"10.1007\/bf02274752","type":"journal-article","created":{"date-parts":[[2005,12,8]],"date-time":"2005-12-08T23:09:44Z","timestamp":1134083384000},"page":"23-27","source":"Crossref","is-referenced-by-count":12,"title":["Global safety of etodolac: Reports from worldwide postmarketing surveillance studies"],"prefix":"10.1007","volume":"10","author":[{"given":"U.","family":"Serni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02274752_CR1","first-page":"151","volume":"32","author":"SL Nelson","year":"1985","unstructured":"Nelson SL, Bergman SA (1985) Relief of dental surgery pain: a controlled 12-hour comparison of etodolac, aspirin, and placebo. Anesth Prog 32: 151\u2013156","journal-title":"Anesth Prog"},{"key":"BF02274752_CR2","first-page":"948","volume":"33","author":"S Ryder","year":"1983","unstructured":"Ryder S, Salom I, Jacob G, Sanda M, Huth J (1983) Etodolac (Ultradol): the safety profile of a new structurally novel nonsteroidal antiinflammatory drug. Curr Ther Res 33: 948\u2013965","journal-title":"Curr Ther Res"},{"key":"BF02274752_CR3","first-page":"682","volume-title":"The pharmacological basis of therapeutics","author":"AG Gilman","year":"1985","unstructured":"Gilman AG, Goodman LS, Rall TW, Murad F (1985) The pharmacological basis of therapeutics, 7th edn. MacMillan, London, pp 682\u2013703","edition":"7th edn."},{"key":"BF02274752_CR4","first-page":"22","volume":"10","author":"PA Bacon","year":"1990","unstructured":"Bacon PA (1990) An overview of the efficacy of etodolac in arthritis disorders. Eur J Rheumatol Inflamm 10: 22\u201334","journal-title":"Eur J Rheumatol Inflamm"},{"key":"BF02274752_CR5","first-page":"82","volume":"2","author":"G Jacob","year":"1985","unstructured":"Jacob G, Sanda M, Mullane J, Kennedy J, Barbetti M, Suleski P (1985) Long-term evaluation of the safety and efficacy of etodolac in the treatment of rheumatoid arthritis. Adv Ther 2: 82\u201395","journal-title":"Adv Ther"},{"key":"BF02274752_CR6","first-page":"1","volume":"2","author":"ML Koonce","year":"1984","unstructured":"Koonce ML, Levy ME (1984) Long-term study of etodolac in the treatment of patients with osteoarthritis. Today Ther Trends 2: 1\u20137","journal-title":"Today Ther Trends"},{"key":"BF02274752_CR7","first-page":"56","volume":"10","author":"M Schattenkirchner","year":"1990","unstructured":"Schattenkirchner M (1990) An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm 10: 56\u201365","journal-title":"Eur J Rheumatol Inflamm"},{"key":"BF02274752_CR8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF02274753","volume":"10","author":"CL Benhamou","year":"1990","unstructured":"Benhamou CL (1990) Large-scale open trials with etodolac (Lodine\u00ae) in France: an assessment of safety. Rheumatol Int 10 (Suppl): 29\u201334","journal-title":"Rheumatol Int"},{"key":"BF02274752_CR9","first-page":"1","volume":"2","author":"M Sanda","year":"1985","unstructured":"Sanda M, Zuchero D, Shand D (1985) Etodolac: safety profile in 992 patients. Adv Ther 2: 1\u201310","journal-title":"Adv Ther"},{"key":"BF02274752_CR10","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/clpt.1984.100","volume":"35","author":"JD Arnold","year":"1984","unstructured":"Arnold JD, Mullane JF, Hayden DM, March L, Hart K, Perdomo CA, Fencik M, Berger AE (1984) Etodolac, aspirin, and gastrointestinal microbleeding. Clin Pharmacol Ther 35: 716\u2013721","journal-title":"Clin Pharmacol Ther"},{"key":"BF02274752_CR11","first-page":"266","volume":"33","author":"J Arnold","year":"1983","unstructured":"Arnold J, Weidler D, Mullane J, Meinders J, Jallad N, Gard D, Hayden D, Perdomo C, Runio T, Burger A (1983) Comparison of etodolac, ibuprofen, indomethacin and naproxen on intestinal microbleeding in normal males. Clin Pharmacol Ther 33: 266 (abstr)","journal-title":"Clin Pharmacol Ther"},{"key":"BF02274752_CR12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/j.1552-4604.1984.tb02780.x","volume":"24","author":"IL Salom","year":"1984","unstructured":"Salom IL, Jacob G, Jallad N, Perdomo CA, Mulane JF, Weidler D (1984) Gastrointestinal microbleeding associated with the use of etodolac, ibuprofen, indomethacin, and naproxen in normal males. J Clin Pharmacol 24: 240\u2013246","journal-title":"J Clin Pharmacol"},{"key":"BF02274752_CR13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/rheumatology\/28.4.329","volume":"28","author":"AS Taha","year":"1989","unstructured":"Taha AS, McLaughlin S, Sturrock RD, Russell RI (1989) Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. Br J Rheumatol 28: 329\u2013332","journal-title":"Br J Rheumatol"},{"key":"BF02274752_CR14","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/gut.27.8.929","volume":"27","author":"JM Daggan","year":"1986","unstructured":"Daggan JM, Dobson AJ, Johnson H et al (1986) Peptic ulcer and nonsteroidal antiinflammatory agents. Gut 27: 929\u2013933","journal-title":"Gut"},{"key":"BF02274752_CR15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/gut.26.8.789","volume":"26","author":"JH McIntosh","year":"1985","unstructured":"McIntosh JH, Byth K, Piper DW (1985) Environmental factors in aetiology of chronic gastric ulcer: a case control study of exposure variables before the first symptoms. Gut 26: 789\u2013798","journal-title":"Gut"},{"key":"BF02274752_CR16","first-page":"63","volume":"15","author":"KD Rainsford","year":"1988","unstructured":"Rainsford KD (1988) Current concepts of the mechanisms of side effects of nonsteroidal antiinflammatory drugs as a basis for establishing research priorities. An experimentalist's view. J Rheumatol 15: 63\u201370","journal-title":"J Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02274752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02274752\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02274752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T12:42:33Z","timestamp":1558010553000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02274752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,1]]},"references-count":16,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[1990,1]]}},"alternative-id":["BF02274752"],"URL":"https:\/\/doi.org\/10.1007\/bf02274752","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,1]]}}}